Back to News
Market Impact: 0.4
Prime Medicine Gets FDA Green Light for Gene Editing Study
Source: benzinga.com
Healthcare & BiotechRegulation & Legislation
Prime Medicine received FDA clearance of its Investigational New Drug application for PM647, enabling clinical development of the one-time curative genetic therapy candidate. The regulatory milestone materially de-risks the program's path into human trials and could move PRME shares, though no clinical efficacy or financial details were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.55
Ticker Sentiment
PRME0.75
More News
- Costco Wholesale, Scholastic and 3 Stocks to Watch Heading Into Friday
- OpenAI rogue agents leaked 53 images from ChatGPT users and reportedly created nearly 1 million links packing encoded bits of info
- Facebook found liable as TikTok settles for $100m over user safety
- What would a US diesel export ban mean for global fuel prices?
- US court rules against Kalshi, says states can regulate prediction markets
- Appeals court rules that states can regulate Kalshi’s sports prediction markets, dealing another legal blow to platforms
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Eli Lilly Q4 2025 Earnings: Revenue Surges 43% as Mounjaro and Zepbound Dominate the GLP-1 Market
- Investment Research Software Costs: A 2026 Budget Framework